The adverse event of interstitial lung disease in patients treated with antibody–drug conjugates
This study analyzed demographic, temporal and outcome profiles of ADC-related ILD cases and identified high-risk signals. These findings help raise awareness and improve the monitoring of adverse events related to ADC. In the future, large-scale prospective studies are needed to further confirm and explore the underlying biological mechanisms.
Authors
- Qing Xu (ORCID: https://orcid.org/0000-0002-0387-7559)
- Nan Fang (ORCID: https://orcid.org/0000-0002-5780-4734)
- Yuqing Wang (ORCID: https://orcid.org/0009-0003-7771-719X)
- Xiang Wang (ORCID: https://orcid.org/0000-0002-5211-7206)
- Hongyan Zhan
- Bin Zhao (ORCID: https://orcid.org/0000-0003-0104-7508)
- Mingbao Lin (ORCID: https://orcid.org/0000-0002-6333-5233)
- Hui Huang
Institutions
- Capital Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1093/oncolo/oyaf228
- Citations
- 5
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 7.59
Funders
- Chinese Pharmaceutical Association
- Peking Union Medical College Hospital